title: Isradipine, catecholamines, and pheochromocytoma.
authors.forename: W
authors.initials: W
authors.lastname: Januszewicz
authors.forename: B
authors.initials: B
authors.lastname: Wocial
authors.forename: J
authors.initials: J
authors.lastname: Chodakowska
authors.forename: T
authors.initials: T
authors.lastname: Feltynowski
authors.forename: M
authors.initials: M
authors.lastname: Lapiński
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000503:physiopathology / Q000652:urine*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D002395:Catecholamines / Q000652:urine*; D004095:Dihydropyridines / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D017275:Isradipine; D008297:Male; D008875:Middle Aged; D010673:Pheochromocytoma / Q000150:complications / Q000503:physiopathology / Q000652:urine*
chemical_list: D002121:Calcium Channel Blockers; D002395:Catecholamines; D004095:Dihydropyridines; D017275:Isradipine